212 related articles for article (PubMed ID: 25122688)
1. Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome.
Wong YF; Micklem CN; Taguchi M; Itonaga H; Sawayama Y; Imanishi D; Nishikawa S; Miyazaki Y; Jakt LM
Stem Cells Transl Med; 2014 Oct; 3(10):1188-98. PubMed ID: 25122688
[TBL] [Abstract][Full Text] [Related]
2. Reduced rRNA expression and increased rDNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes.
Raval A; Sridhar KJ; Patel S; Turnbull BB; Greenberg PL; Mitchell BS
Blood; 2012 Dec; 120(24):4812-8. PubMed ID: 23071274
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.
Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grövdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellström-Lindberg E; Ungerstedt J
Oncotarget; 2017 Apr; 8(17):28812-28825. PubMed ID: 28427179
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
Giachelia M; D'Alò F; Fabiani E; Saulnier N; Di Ruscio A; Guidi F; Hohaus S; Voso MT; Leone G
Leuk Res; 2011 Apr; 35(4):465-71. PubMed ID: 20869114
[TBL] [Abstract][Full Text] [Related]
5. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.
Will B; Zhou L; Vogler TO; Ben-Neriah S; Schinke C; Tamari R; Yu Y; Bhagat TD; Bhattacharyya S; Barreyro L; Heuck C; Mo Y; Parekh S; McMahon C; Pellagatti A; Boultwood J; Montagna C; Silverman L; Maciejewski J; Greally JM; Ye BH; List AF; Steidl C; Steidl U; Verma A
Blood; 2012 Sep; 120(10):2076-86. PubMed ID: 22753872
[TBL] [Abstract][Full Text] [Related]
6. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms.
Hopfer O; Komor M; Koehler IS; Freitag C; Schulze M; Hoelzer D; Thiel E; Hofmann WK
Leuk Res; 2009 Mar; 33(3):434-42. PubMed ID: 18829110
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation.
Hopfer O; Komor M; Koehler IS; Schulze M; Hoelzer D; Thiel E; Hofmann WK
Exp Hematol; 2007 May; 35(5):712-23. PubMed ID: 17577921
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome.
Tran HT; Kim HN; Lee IK; Kim YK; Ahn JS; Yang DH; Lee JJ; Kim HJ
J Korean Med Sci; 2011 Feb; 26(2):207-13. PubMed ID: 21286011
[TBL] [Abstract][Full Text] [Related]
9. Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes.
Matsumoto T; Murakami Y; Yoshida-Sakai N; Katsuchi D; Kanazawa K; Okamura T; Imamura Y; Ono M; Kuwano M
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731802
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.
Hofmann WK; Takeuchi S; Takeuchi N; Thiel E; Hoelzer D; Koeffler HP
Leuk Res; 2006 Nov; 30(11):1347-53. PubMed ID: 16682076
[TBL] [Abstract][Full Text] [Related]
11. A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome.
Asano M; Ohyashiki JH; Kobayashi-Kawana C; Umezu T; Imanishi S; Azuma K; Akahane D; Fujimoto H; Ito Y; Ohyashiki K
Drug Des Devel Ther; 2019; 13():1821-1833. PubMed ID: 31239639
[No Abstract] [Full Text] [Related]
12. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
[TBL] [Abstract][Full Text] [Related]
13. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
Schmelz K; Sattler N; Wagner M; Lübbert M; Dörken B; Tamm I
Leukemia; 2005 Jan; 19(1):103-11. PubMed ID: 15510208
[TBL] [Abstract][Full Text] [Related]
14. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
[TBL] [Abstract][Full Text] [Related]
15. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
[TBL] [Abstract][Full Text] [Related]
16. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
Voso MT; Santini V; Finelli C; Musto P; Pogliani E; Angelucci E; Fioritoni G; Alimena G; Maurillo L; Cortelezzi A; Buccisano F; Gobbi M; Borin L; Di Tucci A; Zini G; Petti MC; Martinelli G; Fabiani E; Fazi P; Vignetti M; Piciocchi A; Liso V; Amadori S; Leone G
Clin Cancer Res; 2009 Aug; 15(15):5002-7. PubMed ID: 19638460
[TBL] [Abstract][Full Text] [Related]
18. CD34+ cells from patients with myelodysplastic syndrome present different p21 dependent premature senescence.
Xiao Y; Wang J; Song H; Zou P; Zhou D; Liu L
Leuk Res; 2013 Mar; 37(3):333-40. PubMed ID: 23219618
[TBL] [Abstract][Full Text] [Related]
19. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
Nilsson L; Astrand-Grundström I; Anderson K; Arvidsson I; Hokland P; Bryder D; Kjeldsen L; Johansson B; Hellström-Lindberg E; Hast R; Jacobsen SE
Blood; 2002 Jul; 100(1):259-67. PubMed ID: 12070035
[TBL] [Abstract][Full Text] [Related]
20. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Yang Y; Zhang Q; Xu F; Chang C; Li X
Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
